Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946272 | 0.90 | PPARA (0.56) | CHRM2CHRM1CHRM3DAOCETP | |
| SCHEMBL7610809 | 0.88 | PPARA (0.62) | CHRM2CHRM1CHRM3DAOCETP | |
| SCHEMBL178310 | 0.87 | CHRM2 (0.55) | CHRM2CHRM1CHRM3DAOCETP | |
| SCHEMBL22096418 | 0.87 | PPARA (0.64) | CHRM2CHRM1CHRM3DAOPPARG | |
| SCHEMBL2096533 | 0.86 | PPARA (0.46) | CHRM2CHRM1CHRM3DAOCETP | |
| Hydrochloric Acid SCHEMBL21272596 | 0.84 | CHRM2 (0.52) | CHRM2CHRM1CHRM3DAOCETP | |
| SCHEMBL14670931 | 0.84 | PPARA (0.52) | CHRM2CHRM1CHRM3CETPPPARG | |
| SCHEMBL12061947 | 0.83 | CHRM2 (0.56) | CHRM2CHRM1CHRM3DAOCETP | |
| SCHEMBL8515213 | 0.82 | SLC6A4 (0.47) | CHRM2CHRM1CHRM3DAOGRIN2B | |
| SCHEMBL8505613 | 0.82 | CHRM2 (0.56) | CHRM2CHRM1CHRM3DAOCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2020-06-04 | — | — | US | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2348023-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9394261-B2 | Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs | NATIONAL YANG-MING UNIVERSITY (TW) | 2016-07-19 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319163-B2 | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CHRM2 3586/4885CHRM1 2619/4885CHRM3 4326/4885 |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | CHRM2 1873/4885CHRM1 2416/4885CHRM3 862/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | CHRM2 4661/4885CHRM1 4831/4885CHRM3 4625/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CHRM2 4405/4885CHRM1 4414/4885CHRM3 3741/4885 |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, PLA2G10, LPCAT1 | CHRM2 1892/4885CHRM1 2161/4885CHRM3 1455/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | CHRM2 4064/4885CHRM1 3696/4885CHRM3 4061/4885 |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | CHRM2 4604/4885CHRM1 4572/4885CHRM3 4778/4885 |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | CHRM2 1892/4885CHRM1 2161/4885CHRM3 1455/4885 |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, LPCAT1, PLA2G10 | CHRM2 2001/4885CHRM1 2238/4885CHRM3 1600/4885 |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | CHRM2 4828/4885CHRM1 4819/4885CHRM3 4837/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | CHRM2 2687/4885CHRM1 3241/4885CHRM3 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.